Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $344
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Why United Therapeutics (UTHR) Is a Top Growth Stock for the Long-Term
Express News | United Therapeutics Corp : Leerink Partners Raises Target Price to $344 From $338
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Express News | United Therapeutics Corp : Morgan Stanley Raises Target Price to $321 From $310
Express News | United Therapeutics Corp : Morgan Stanley Cuts to Equal-Weight From Overweight
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
United Therapeutics Is Maintained at Buy by TD Cowen
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
United Therapeutics Price Target Raised to $321.00/Share From $310.00 by Morgan Stanley